Three distinct generations of epigenetic clocks offer researchers measurable biological insights by predicting chronological age, mortality risks, and the real-time pace of cellular aging.
Many people search for biological age tests after receiving conflicting numbers from different commercial laboratories. A person might take two tests in the same month and learn that one clock rates them five years younger than their calendar age, while another rates them three years older.
This discrepancy creates immediate confusion about which test is accurate. The short answer is that epigenetic clocks are not interchangeable tools measuring a single biological property.
Instead, each clock is a distinct statistical model built from a specific dataset and trained to answer a specific scientific question. This guide provides a comprehensive comparison of first-generation age estimators, mortality-oriented models, pace-of-aging metrics, and tissue-focused algorithms to clarify what these tools measure and where their limits lie.
To understand why epigenetic clocks differ, one must first look at the biological data that powers them. DNA methylation is a biochemical modification where small chemical tags, known as methyl groups, attach to cytosine bases in the genome. These attachments occur primarily at cytosine-guanine dinucleotide sites, commonly referred to as CpG sites.
Methylation patterns change across the human lifespan in response to developmental programming, environmental exposures, and cellular division. Researchers measure these patterns using laboratory microarrays that assess hundreds of thousands of CpG sites simultaneously across the genome.
An epigenetic clock is an algorithm that selects a specific subset of these CpG sites. The model assigns mathematical weights, or coefficients, to each chosen site based on statistical regressions. When a new sample is processed, the algorithm multiplies the methylation level at each designated CpG site by its weight, sums the values, and produces a final score.
The fundamental variable separating one clock from another is its training target. The training target is the specific real-world outcome that the algorithm was programmed to predict during its development.
A clock trained to guess how many years have passed since birth will identify different CpG sites than a clock trained to estimate the risk of death. Consequently, the term "epigenetic age" does not describe a single universal biological property. It is simply the numerical output of a mathematical model applied to a biological sample.
When evaluating any epigenetic clock study, it is essential to identify the underlying evidence stage. Most published clock research relies on observational human data derived from large cohort studies and epidemiological biobanks.
While cell culture and animal models help researchers study the biochemistry of methylation, human clocks are statistical models evaluated across human population samples. These models measure surrogate molecular markers rather than direct, confirmed changes in disease incidence or lifespan.
First-generation epigenetic clocks were developed to solve a straightforward statistical challenge. Developers asked whether algorithms could accurately predict a person's chronological age using only DNA methylation patterns.
These early models treated calendar time as the primary truth metric. The algorithms searched large methylation datasets to find CpG sites whose chemical status correlated most tightly with chronological age across different individuals.
Introduced in 2013 by biostatistician Steve Horvath, the multi-tissue clock was a major methodological milestone in geroscience. Horvath assembled public DNA methylation datasets spanning 51 different healthy tissues and cell types, alongside various cancer samples.
Using penalized regression techniques, the algorithm selected 353 specific CpG sites that together could estimate chronological age across most human tissues.
The multi-tissue clock demonstrated that age-related epigenetic changes follow a predictable trajectory across distinct organs. Its mathematical output is expressed in years, providing an estimate of chronological age based on methylation patterns.
When a person's predicted age exceeds their chronological age, the difference is often described as positive epigenetic age acceleration. Conversely, a predicted age below calendar age is termed negative age acceleration.
The broad applicability of the multi-tissue clock made it an invaluable reference tool for comparative biology. Researchers could apply a single standardized formula to liver biopsies, brain specimens, blood samples, and cell cultures.
However, broad applicability across tissues does not mean the model provides identical precision or identical biological meaning in every specimen. The clock answers an age-estimation question, tracking how closely a tissue's methylation profile resembles the typical profile of someone at that calendar age.
Published around the same time as Horvath's model, the Hannum clock took a tissue-focused approach. Gregory Hannum and colleagues trained their model exclusively on whole blood samples collected from adult individuals.
The resulting algorithm selected 71 CpG sites optimized specifically to predict chronological age from blood-derived DNA.
Because the Hannum clock was trained strictly on blood, its selected CpG sites and statistical weights differ substantially from Horvath's multi-tissue model. The Hannum clock performs reliably when assessing human blood specimens.
However, applying it to other tissues can reduce its predictive precision because methylation baselines vary across cell types.
First-generation clocks remain useful for specific scientific questions. They provide a solid framework for forensic age estimation, demographic research, and sample validation in laboratory biobanks.
They also allow researchers to observe how broad methylation patterns change across long periods of chronological time.
Despite these strengths, first-generation models have clear limitations when applied to health assessments. Because these models were trained exclusively to predict calendar time, their mathematical optimization penalizes markers that deviate from chronological age.
Many biological variations related to lifestyle, subclinical disease, and physical fitness are filtered out by the algorithm if they do not track calendar years. As a result, first-generation clocks show relatively weak associations with mortality risk, physical functioning, and chronic disease incidence when compared to newer models.
A high correlation with chronological age confirms that a clock can estimate a person's birthday with reasonable accuracy. It does not prove that the clock can detect variations in physiological health, disease vulnerability, or individual healthspan.
Recognizing the clinical limitations of first-generation models, researchers developed second-generation epigenetic clocks. Instead of training algorithms to predict calendar age, developers shifted their focus toward physiological health status and mortality risk.
These second-generation models were designed to identify epigenetic patterns that differentiate healthy individuals from those with elevated health risks, even when both individuals share the same chronological age.
Developed by Morgan Levine and colleagues in 2018, DNAm PhenoAge utilized a two-step training strategy. The researchers recognized that clinical chemistry panels often capture physiological decline more effectively than calendar age alone.
To build their target, they analyzed multi-decade mortality and health records from thousands of participants in the National Health and Nutrition Examination Survey (NHANES III).
In the first step, researchers used a penalized survival model to evaluate 42 candidate clinical biomarkers. They narrowed this list down to nine routine clinical blood markers that, when combined with chronological age, strongly predicted multi-system mortality risk:
Together, these nine biomarkers and chronological age formed a composite clinical score called Phenotypic Age. In the second step, researchers trained an elastic-net regression model on whole blood DNA methylation data to predict this composite score.
The resulting algorithm, DNAm PhenoAge, uses 513 CpG sites to generate a score expressed in units of years.
DNAm PhenoAge associates significantly with all-cause mortality, cardiovascular disease, cancer risk, physical functioning, and Alzheimer's disease pathology in observational cohorts.
However, PhenoAge is a statistical estimator of a constructed composite score, not a direct laboratory measurement of the nine clinical biomarkers themselves. An elevated PhenoAge score indicates that a person's blood methylation profile resembles that of individuals with poorer clinical chemistry profiles and higher mortality risk in historical cohorts.
Introduced in 2019 by Ake Lu and Steve Horvath, DNAm GrimAge adopted an innovative two-stage proxy design focused directly on survival prediction. Rather than predicting standard clinical chemistry panels, the developers sought to construct methylation-based surrogate markers for circulating plasma proteins associated with chronic disease, alongside a surrogate marker for cumulative tobacco exposure.
The developers first identified several physiological proteins and risk factors linked to morbidity and mortality. They built individual DNA methylation estimators for these components, creating surrogate epigenetic scores for seven plasma proteins and one behavioral risk factor:
In the second stage, the algorithm combined these methylation-based surrogate scores along with chronological age and sex into a single composite mortality risk index. The resulting score, named GrimAge, is expressed in units of years.
In large epidemiological validation cohorts, GrimAge demonstrated strong predictive power for time to death, coronary heart disease, and incident cancer. Initial publications reported highly significant Cox proportional hazards regression values, including p-values of 2.0 × 10⁻⁷⁵ for time to death, 6.2 × 10⁻²⁴ for coronary heart disease, and 1.3 × 10⁻¹² for cancer incidence.
GrimAge also correlates with computed tomography measures of visceral adiposity and fatty liver infiltration.
Although both PhenoAge and GrimAge are categorized as second-generation mortality-oriented clocks, they are built on different biological frameworks. PhenoAge is trained on a composite phenotype derived from standard clinical chemistry and hematology panels.
GrimAge is trained on surrogate DNA methylation estimators for circulating plasma proteins and historical tobacco exposure.
Because these models rely on different training targets and CpG sites, a person can receive different relative rankings on PhenoAge compared to GrimAge. For instance, an individual with normal liver and kidney markers but elevated inflammatory or vascular risk signals may score differently across the two tests.
Neither score is mathematically incorrect; each model simply evaluates distinct dimensions of physiological risk. Researchers and clinicians studying age biomarkers and diagnostics must evaluate each model based on its specific training parameters.
While first- and second-generation clocks estimate biological status at a single cross-sectional point in time, a third category of epigenetic tools was developed to measure the speed at which an individual is currently aging. These algorithms are known as pace-of-aging measures.
To use a mechanical analogy, chronological and mortality clocks function like an odometer on a car, measuring total accumulated distance. A pace-of-aging tool functions like a speedometer, measuring the rate of ongoing operational strain per unit of time.
DunedinPACE (Pace of Aging Calculated from the Epigenome) was developed by Daniel Belsky and colleagues using longitudinal data from the renowned Dunedin Study. The Dunedin Study tracked a population-representative birth cohort of individuals born between 1972 and 1973 in Dunedin, New Zealand.
Researchers monitored these individuals across four distinct adult assessment periods at ages 26, 32, 38, and 45.
At each assessment point, researchers collected physiological data across 19 separate biomarkers representing multiple organ systems:
By analyzing the rate of change across these 19 biomarkers over a 20-year span, researchers calculated an individualized slope of multi-system physiological decline for each participant.
They then trained an elastic-net regression model to detect this longitudinal trajectory using blood DNA methylation data collected at age 45. The resulting algorithm, DunedinPACE, uses 173 CpG sites to estimate the current rate of biological aging from a single blood sample.
The output of DunedinPACE is expressed as a rate relative to a normative reference value of 1.0 biological year per chronological year. A score of 1.0 indicates that an individual is accumulating multi-system physiological decline at the expected population average rate.
A score of 1.15 suggests that the person is aging at a pace 15 percent faster than average, accumulating approximately 1.15 years of physiological decline for every calendar year. Conversely, a score of 0.85 indicates a slower pace of aging.
In validation cohorts, DunedinPACE demonstrated high test-retest reliability and associated significantly with incident morbidity, physical limitations, cognitive decline, and mortality. In some cohort studies, DunedinPACE provided incremental predictive value for health outcomes beyond the risk stratification offered by GrimAge.
A person's pace of aging and their cumulative biological age score can diverge substantially. For example, an individual who experienced substantial physiological stress or illness in early adulthood may show an elevated score on an accumulated mortality clock like GrimAge.
If that individual subsequently adopts healthier lifestyle habits or medical treatments, their ongoing rate of decline may slow down. In such cases, their DunedinPACE score might drop below 1.0, while their cumulative GrimAge score remains elevated due to historical damage.
Understanding this distinction is vital for clinical trial design and personal health tracking. A pace-of-aging metric is structured to detect short-term changes in the velocity of biological decline, whereas cumulative age estimators reflect total historical accumulation over decades.
Neither score invalidates the other; they simply measure different aspects of the aging process.
DNA methylation is the primary epigenetic mechanism that allows cells sharing an identical genetic code to differentiate into distinct tissues, such as skin, liver, or bone marrow. Because methylation patterns are intrinsically tissue-specific, the performance of an epigenetic clock depends heavily on the biological sample analyzed.
A common misconception is that an epigenetic clock trained on blood can be applied interchangeably to saliva, cheek swabs, or organ biopsies. Comparative studies demonstrate that applying blood-derived models to oral tissues often produces inaccurate age estimates.
Saliva and buccal swabs contain mixtures of epithelial cells and localized immune cells in varying proportions. If an algorithm is not specifically calibrated for those cellular mixtures, the resulting score can be distorted.
To address cross-tissue demands, Steve Horvath and colleagues developed the Skin and Blood clock in 2018. This model was trained on human keratinocytes, skin fibroblasts, coronary artery endothelial cells, whole blood, and saliva.
The resulting algorithm selected 391 CpG sites optimized to maintain high accuracy across both dermal and hematological samples.
The Skin and Blood clock has proven valuable in dermatological research, cellular aging studies, and general cohort profiling. In large epidemiological cohorts, age acceleration calculated from this model has shown associations with all-cause mortality.
Furthermore, researchers have reported reliable chronological age correlations when applying the clock to sorted neurons, glial cells, liver specimens, and bone samples. However, demonstrating high correlation in specific experimental settings does not guarantee that the clock reflects organ-specific functional health.
Age estimation poses unique challenges during childhood and adolescence, when developmental methylation shifts occur at a rapid pace. Standard adult clocks often perform poorly when applied to pediatric samples because the developmental trajectory differs fundamentally from adult senescence.
In a comprehensive comparative study evaluating pediatric tissues, the best-performing clock varied depending on the biological sample:
This variation underscores that no single clock is universally optimal across all human tissues and developmental stages. A clock validated for a specific tissue, age group, or clinical population should not be assumed to work with equal reliability outside its validated context.
An epigenetic measurement derived from a specific tissue sample should not be interpreted as a comprehensive medical diagnosis of that organ's health. For instance, an accelerated epigenetic score in a blood sample does not prove the presence of leukemia or immune failure.
Similarly, an elevated score from a skin biopsy does not confirm skin cancer or structural tissue failure.
These algorithms quantify the statistical alignment between a sample's methylation state and a reference dataset. They reflect population-level trends rather than precise diagnostic criteria for individual patients.
Clinicians and individuals must interpret tissue-derived scores within the bounds of published validation studies, recognizing that epigenetic clocks remain research tools rather than diagnostic instruments.
Consumers and researchers often ask why different epigenetic clocks yield divergent results for the same person. When one test reports that an individual is 42 years old while another reports 50, it is tempting to assume that one of the laboratories made a testing error.
In reality, these differences stem from fundamental variations in model architecture, reference datasets, and mathematical formulations.
As discussed throughout this guide, clocks are mathematically optimized to predict different target variables. First-generation models aim for chronological age, second-generation models focus on mortality and clinical surrogates, and pace-of-aging metrics track multi-system rates of change.
Because calendar age, health risk, and aging velocity are distinct physiological properties, their corresponding algorithms naturally focus on different CpG sites across the genome.
A high score on a mortality clock does not require a high score on a chronological clock. An individual who smokes heavily may display substantial GrimAge acceleration due to smoking-associated CpG alterations, while their Horvath multi-tissue score remains relatively close to their calendar age.
The two clocks are answering fundamentally different questions about the same biological sample.
The overlap of specific CpG sites among popular epigenetic clocks is surprisingly low. Out of hundreds of thousands of possible sites on a measurement array:
Each algorithm applies unique statistical weightings to its selected sites. Because these algorithms sample different genomic regions, they capture distinct biological pathways.
A physiological change that alters methylation at PhenoAge-specific CpGs might leave GrimAge or DunedinPACE sites unaffected. Consequently, two clocks can both be internally valid within their original study frameworks while providing completely different biological age estimates for an individual.
Even when researchers evaluate the same clock model, discrepancies can arise from how age acceleration is calculated. In scientific literature, two distinct mathematical approaches are commonly used:
These two calculations do not yield identical values, particularly at the younger and older extremes of a cohort where regression-to-the-mean effects occur.
When comparing findings across different scientific papers or commercial laboratory reports, one must verify the exact calculation method used. Reporting an "accelerated epigenetic age" without defining the underlying formula leads to inaccurate comparisons.
Aging is a complex, multi-system process that does not advance uniformly across all cells and tissues. Epigenetic drift, genomic instability, cellular senescence, metabolic dysfunction, and chronic inflammation can progress at different rates within the same body.
An epigenetic clock that primarily reflects inflammatory signaling will produce a different risk profile than one that captures cellular division counts or metabolic stress.
Without a fully defined molecular mechanism linking every CpG site to a specific pathology, a single epigenetic clock score cannot be treated as a definitive summary of an individual's overall aging process.
While epigenetic clocks are valuable research instruments in geroscience, translating these tools into individual health assessments presents several methodological hurdles. Interpreting personal results requires a clear understanding of laboratory variability, cellular heterogeneity, and current regulatory standards.
Microarray platforms that measure DNA methylation are subject to technical variability. Factors such as laboratory ambient temperature, reagent batch differences, pipetting inconsistencies, and array chip positions can introduce measurement noise.
In practical terms, if an individual splits a single blood draw into two separate vials and sends them to different laboratories, the resulting epigenetic age scores can vary by several years.
While population-level epidemiological studies can average out this technical noise across thousands of participants, individual test-takers are highly sensitive to single-run technical variation. Researchers have developed newer computational tools and principal component methods to reduce array noise, but technical variation remains an important consideration.
Whole blood is not a uniform fluid; it is a complex mixture of diverse cell types, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Each immune cell subtype possesses its own distinct DNA methylation profile.
When an individual experiences a transient infection, psychological stress, or mild allergic reaction, their bone marrow shifts the relative proportions of circulating white blood cells.
Because an epigenetic clock analyzes total DNA extracted from the entire blood sample, changes in white blood cell proportions can alter the resulting score.
A shift in estimated epigenetic age might simply reflect a temporary rise in granulocytes following an infection rather than an acceleration in underlying biological aging. While algorithms can adjust mathematically for estimated cell counts, cellular composition remains a significant variable in blood-based testing.
In geroscience research, a central goal is determining whether epigenetic clocks can serve as validated surrogate endpoints for clinical interventions.
A validated surrogate endpoint is a biomarker that reliably substitutes for a hard clinical outcome, such as cardiovascular events, cancer incidence, or overall mortality.
Currently, regulatory agencies such as the U.S. Food and Drug Administration (FDA) have not formally validated any epigenetic clock as a primary surrogate endpoint for clinical trials. Demonstrating that a drug, diet, or lifestyle change lowers an epigenetic clock score does not guarantee that the intervention will prevent disease or extend human lifespan.
For a biomarker to achieve formal surrogate status, researchers must demonstrate that treatment-induced changes in the marker directly account for the treatment's effect on clinical endpoints. Establishing this rigorous causal link requires large-scale, randomized, controlled human trials with long-term clinical follow-up.
Until those trials are complete, changes in clock scores should be viewed as preliminary biological signals rather than demonstrated medical benefits.
To prevent misinterpretation, researchers and individuals must maintain clear boundaries around what current epigenetic data can and cannot prove:
To assist readers evaluating clinical studies, consumer tests, or biological age testing literature, this section outlines the primary biomarkers and terminology used in epigenetic clock research.
For readers interested in geroscience, biology of aging research, or reviewing clinical literature, understanding how to assess epigenetic clock data is an essential skill.
The following practical checklist provides a structured framework you can apply this week when reading scientific papers, evaluating testing platforms, or discussing laboratory results with a healthcare professional.
To read more about emerging research on geroscience, biomarkers, and healthspan diagnostics, explore the latest educational resources in the AgeAmaze research archives.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
